Ceritinib (LDK-378)
目录号: A13238
ALK 抑制剂
LDK378 是一种高度选择性的、口服生物利用度高的、与 ATP 竞争的小分子抑制剂,针对 ALK (间变性淋巴瘤激酶),这是一种受体酪氨酸激酶,被认为是重要的肺癌药物靶标。
Discription | LDK378 is a highly selective, orally bioavailable and ATP-competitive small molecule inhibitor of ALK (Anaplastic Lymphoma Kinase), a receptor tyrosine kinase considered to be an important lung cancer drug target. | |||||
---|---|---|---|---|---|---|
Targets |
|
|||||
Cell Research |
|
目录号 | A13238 |
---|---|
分子式 | C28H36ClN5O3S |
分子量 | 558.14 |
CAS号 | 1032900-25-6 |
SMILES | CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl |
其他名称 | LDK378,LDK 378 |
储存条件 | Store lyophilized at -20ºC, keep desiccated. |
In vitro | DMSO | Warmed: 18 mg/mL (32.25 mM) | |
Water | Insoluble | ||
Ethanol | 3 mg/mL (5.37 mM) | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 17.92 mL | 89.58 mL | 179.17 mL |
0.5 mM | 3.58 mL | 17.92 mL | 35.83 mL |
1 mM | 1.79 mL | 8.96 mL | 17.92 mL |
5 mM | 0.36 mL | 1.79 mL | 3.58 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2